Quantcast

Latest Ipilimumab Stories

2008-09-15 12:00:09

Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced updated survival data from three Phase 2 studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV) who had previously been treated. Study results show that approximately half of patients who received ipilimumab (10 mg/kg) remained alive beyond one year. The results are based on follow-up of the patient population from studies 008, 022 and 007 treated with 10 mg/kg of...

2008-08-28 06:00:18

OSLO, August 28 /PRNewswire-FirstCall/ -- - Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC) Algeta ASA , the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing...

2008-08-12 12:00:34

PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount. The Phase 2A clinical trial is...

2008-08-07 12:00:18

Medarex has announced the allowance of an investigational new drug application filed with the FDA for MDX-1105, for the treatment of patients with selected advanced or recurrent solid tumors, specifically renal cell carcinoma, melanoma, non-small cell lung cancer or epithelial ovarian cancer. The open-label, multi-dose, dose-escalation Phase I clinical trial is expected to enroll up to 46 patients with selected advanced or recurrent solid tumors. This trial is designed to establish and...

2008-08-05 09:00:13

PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1105, for the treatment of patients with selected advanced or recurrent solid tumors, specifically renal cell carcinoma, melanoma, non-small cell lung cancer or epithelial ovarian cancer. MDX-1105 is a fully human antibody that targets the PD-L1 pathway to promote enhanced T-cell...

2008-08-01 18:00:08

Cell Genesys, Inc. (Nasdaq:CEGE) today reported financial results for the second quarter ended June 30, 2008. The net loss for the quarter ended June 30, 2008, was $2.8 million ($0.03 per fully diluted share), compared to a net loss of $1.9 million ($0.03 per fully diluted share) for the corresponding period in 2007. The company ended the quarter with approximately $165.5 million in cash, cash equivalents and short-term investments. This includes the $50.0 million payment received from Takeda...

2008-07-16 06:00:13

By Annette Wells By ANNETTE WELLS REVIEW-JOURNAL Randy Irwin is the ultimate guinea pig. He's the first to try out an experimental treatment by New Jersey- based Medarex for kidney cancer to determine whether it works and to observe possible side effects. Hopes were that his tumor would shrink or disappear - or at the very least remain in check - because of the treatment. But earlier this month the 50-year-old Las Vegas resident learned that, after three treatments in six weeks,...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related